Nanaimo BC-based cannabis licensed producer (LP)
Tilray Inc. (
NASDAQ: TLRY) has announced the launch of Symbios – a complement to the Company’s existing medical brand portfolio in Canada.
The company said this new brand was developed to provide a broader spectrum of formats and unique cannabinoid ratios at a better price point while offering medical patients a full comprehensive assortment of products, including flower, oils, and pre-rolls for their health and wellness regiment.
Irwin D. Simon, Tilray’s Chief Executive Officer, commented:
“Medical cannabis innovation and patient care are core to the new Tilray’s business and global growth strategy. As we look ahead, we remain focused on building momentum across our three medical brands – Symbios, Aphria, and Tilray – while meeting the large and growing demand for new, high-quality cannabis products that promote health, wellness, and wellbeing.”
TLRY stock was up just under 6% at the end of day trading on the Nasdaq.
Full article
here.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub on Stockhouse.